As the search continues for treatments for Covid-19, the results from a number of studies have led to changes in the advice on which drugs to give people who are suffering from the disease.
The European Medicines Agency and the United States National Institutes of Health have recently stated that one previously promising treatment – the antiparasitic drug, ivermectin – is not recommended for use in routine management of Covid-19 patients.
Despite these decisions, support for ivermectin has been circulating on social media and in WhatsApp groups, with rumours abounding that the drug is being blocked on purpose. Some have dubbed it the “new hydroxycholoroquine”, after a treatment that received a significant amount of online support but was found in trials to be ineffective against Covid-19.
Ivermectin: why a potential COVID treatment isn t recommended for use ohiostandard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ohiostandard.com Daily Mail and Mail on Sunday newspapers.
Genkyotex: Disclosure of the Total Number of Voting Rights and Shares Pursuant to Article L. 233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the French Financial Markets Authority
Regulatory News:
Genkyotex shares
Date
(1): 14,083,408
meeting
(2): 14,074,165
(1) In accordance with Article 223-111 of the AMF s General Regulation, this number of shares is calculated based on all shares carrying the right to vote, including those stripped of voting rights.
(2) Less shares stripped of voting rights.
About Genkyotex
Genkyotex is the leading biopharmaceutical company in NOX therapies, listed on the Euronext Paris and Euronext Brussels markets. Its unique platform enables the identification of orally available small-molecules which selectively inhibit specific NOX enzymes that amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. Genkyotex is developing a pipeline
Qorvo Biotechnologies granted emergency use authorization, awarded $24 4M contract, to produce COVID-19 rapid test wraltechwire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wraltechwire.com Daily Mail and Mail on Sunday newspapers.
Key Capital Corporation: Key Capital Launches Unique Natural Mental Health Supplement - MaxCellLife MIND
NEW YORK, NY / ACCESSWIRE / April 8, 2021 / KEY CAPITAL CORPORATION (OTC PINK:KCPC)
advises that in association with its partner, global oral pill vaccine pioneer Immunitor (Thailand) Co., Ltd, the Company is today launching its unique M.vaccae and magnesium dietary supplement in the $18 billion Anxiety and Stress market.
MaxCellLife MIND is now available through the Company s marketing website https://MaxCellLife.com.
Our Market - Stress, Anxiety, and Depression
As is extensively reported, in our fast-paced modern world Stress, Anxiety, Depression, and often associated serious mental health incidence is increasingly prevalent.